ARCHIVES

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Cost of Care: Medicare Patients Charged More In Outpatient Care Settings

November 1, 2013

IOM Recommends FDA Consolidate Each Drug’s Lifetime History

May 4, 2012

It’s Official : PRI Wins Massive FCRF Contract ; DMS Keeps Library, Lands Computer Servicea

September 18, 1987

Report Urges Enhancement Of Cancer Data Systems.

October 20, 2000

In Brief: NCAB to Hear Program Review, Reports On AIDs Monoclonal Antibodies, Cancer Research at Drew

November 25, 1983

Benefit Of Chemotherapy Depends ER Status

April 28, 2006